These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35868334)

  • 1. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.
    Kårhus ML; Brønden A; Forman JL; Haaber A; Knudsen E; Langholz E; Dragsted LO; Hansen SH; Krakauer M; Vilsbøll T; Sonne DP; Knop FK
    Lancet Gastroenterol Hepatol; 2022 Oct; 7(10):922-931. PubMed ID: 35868334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial.
    Borup C; Vinter-Jensen L; Jørgensen SPG; Wildt S; Graff J; Gregersen T; Zaremba A; Borup Andersen T; Nøjgaard C; Timm HB; Rainteau D; Hansen SH; Rumessen JJ; Munck LK
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):321-331. PubMed ID: 36758570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.
    Kårhus ML; Brønden A; Lyng Forman J; Haaber A; Vilsbøll T; Sonne DP; Knop FKK
    BMJ Open; 2021 Feb; 11(2):e044711. PubMed ID: 33558360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study.
    Beigel F; Teich N; Howaldt S; Lammert F; Maul J; Breiteneicher S; Rust C; Göke B; Brand S; Ochsenkühn T
    J Crohns Colitis; 2014 Nov; 8(11):1471-9. PubMed ID: 24953836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
    O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
    Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
    Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
    Camilleri M; Acosta A; Busciglio I; Boldingh A; Dyer RB; Zinsmeister AR; Lueke A; Gray A; Donato LJ
    Aliment Pharmacol Ther; 2015 Mar; 41(5):438-48. PubMed ID: 25594801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
    von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
    Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Ahrén B; Torffvit O; Attvall S; Ekelund M; Filipsson K; Tengmark BO; Sjöberg S; Pehrsson NG
    BMJ; 2015 Oct; 351():h5364. PubMed ID: 26512041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study.
    Beysen C; Murphy EJ; Deines K; Chan M; Tsang E; Glass A; Turner SM; Protasio J; Riiff T; Hellerstein MK
    Diabetologia; 2012 Feb; 55(2):432-42. PubMed ID: 22134839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
    Buse JB; Nauck M; Forst T; Sheu WH; Shenouda SK; Heilmann CR; Hoogwerf BJ; Gao A; Boardman MK; Fineman M; Porter L; Schernthaner G
    Lancet; 2013 Jan; 381(9861):117-24. PubMed ID: 23141817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
    Miyagawa J; Odawara M; Takamura T; Iwamoto N; Takita Y; Imaoka T
    Diabetes Obes Metab; 2015 Oct; 17(10):974-83. PubMed ID: 26179187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SeHCAT [tauroselcholic (selenium-75) acid] for the investigation of bile acid malabsorption and measurement of bile acid pool loss: a systematic review and cost-effectiveness analysis.
    Riemsma R; Al M; Corro Ramos I; Deshpande SN; Armstrong N; Lee YC; Ryder S; Noake C; Krol M; Oppe M; Kleijnen J; Severens H
    Health Technol Assess; 2013 Dec; 17(61):1-236. PubMed ID: 24351663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.